A study published in The Lancet Regional Health Europe involving approximately 80,000 patients with type 2 diabetes found that discontinuing GLP-1 receptor agonists was associated with a significantly increased risk of cardiovascular events and death. Specifically, patients who stopped taking the medication faced double the likelihood of heart attacks, strokes, or cardiovascular-related deaths within three to four years compared to those who continued treatment. Overall mortality in the group that discontinued therapy was nearly five times higher, despite similar baseline characteristics between the two groups. Researchers noted that standard risk factors like weight and blood glucose levels did not fully account for this elevated risk, suggesting the drugs provide direct protective benefits beyond metabolic control. Medical experts emphasized that while these findings highlight the importance of continuous treatment for cardiovascular protection, they do not necessarily apply to individuals using the drugs solely for weight loss.
Bias read (Center): The article presents medical research findings neutrally, citing specific statistical data and including balanced expert commentary that contextualizes the limitations of the observational study design.





